Aqua Medical Secures FDA IDE to Study its Breakthrough Endoscopic Technology for the treatment of Type 2 Diabetes
PLEASANTON, Calif., Nov. 4, 2025 /PRNewswire/ — Aqua Medical, a company advancing Endoscopic Metabolic Restoration for type 2 diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for its pilot clinical trial of the Proximal Intestinal Mucosal Ablation (PIMA) procedure using the company’s proprietary radiofrequency vapor ablation (RFVA) […]